Cargando…
Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus
Interferon (IFN)-based therapy for hepatitis C virus (HCV) infection has recently been replaced by IFN-free direct-acting antiviral (DAA)-based therapy, which has been established as a 1(st) line therapy with high efficacy and tolerability due to its reasonable safety profile. Resistance-associated...
Autores principales: | Sato, Ken, Uraoka, Toshio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189846/ https://www.ncbi.nlm.nih.gov/pubmed/30344416 http://dx.doi.org/10.3748/wjg.v24.i38.4304 |
Ejemplares similares
-
Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
por: Sato, Ken, et al.
Publicado: (2022) -
Prognosis of late elderly patients with chronic hepatitis C after achieving a sustained viral response by direct‐acting antivirals
por: Takakusagi, Satoshi, et al.
Publicado: (2020) -
Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately
por: Tojima, Hiroki, et al.
Publicado: (2021) -
Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals
por: Takakusagi, Satoshi, et al.
Publicado: (2021) -
Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)